Navigation Links
National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
Date:5/28/2008

MOUNTAINSIDE, N.J., May 28 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI - News) today announced that it is taking steps to change its name to Proteonomix, Inc. The change will also entail a change in its trading symbol.

Michael Cohen, President/CEO, stated: "Our new name reflects the fact that we are emerging out of our research and development stage and commencing the commercialization of our technologies. These technologies relate in great part to the identification of proteins, and their structure and functions within the emerging biotherapeutics field."

Further, the Company intends to begin marketing its current portfolio biomarkers to research laboratories globally.

National Stem Cell Holding, Inc. is focused on developing therapeutics based upon the use of human cells and their derivatives by developing proprietary stem cell therapeutics with particular focus on diabetes and cardiac diseases. Stem Cell Therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells and promises treatment of diseases previously regarded as incurable.

In addition to its work with stem cell therapeutics, it is also developing the capabilities of its wholly-owned subsidiaries: the Sperm Bank of NY (tissue bank) and in vitro fertilization (IVF) laboratory and National Stem Cell Blood Laboratories Inc. (cord blood bank) and its affiliate, ProteoDerm (anti-aging cosmetics derived from stem cells).

The Company is headquartered in Mountainside, NJ. For more information, please contact us at the company website: http://www.nationalstemcell.com or http://www.pinksheets.com .

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc. (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc.(cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-facetted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Michael Cohen

187 Mill Lane

Mountainside, NJ 07052

Phone: (212)792-6188

ir@nationalstemcell.com


'/>"/>
SOURCE National Stem Cell Holding, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Israeli Scientists Recipients of 2008 International Adult Stem Cell Award
2. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
3. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
4. MagSense to Exhibit Its Scientific and Clinical Applications at International Magnetic Carriers Conference
5. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
6. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
7. International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
10. Chindex International Announces Shelf Registration, Related Strategy and Guidance
11. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a ... from the National Institute of Mental Health (NIMH) for the further advancement of the ... PROZOR technology and is expected to deliver therapeutic levels of olanzapine for a ...
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" ... in China, today announced its financial results for the fourth ... Quarter 2016 Financial Highlights Total sales ... RMB terms, or increased by 13.6% in USD terms to ... 2015. Gross profit increased by 13.3% to ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/26/2017)... PANAMA CITY , Jan. 26, 2017  Crossmatch, ... today unveiled a new solution aimed at combatting fraud, ... The solution was introduced at the Action on Disaster ... a key meeting point for UN agencies and foreign ... Fraud, waste and abuse are a largely ...
Breaking Biology News(10 mins):